These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 33174532)

  • 1. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1
    Ruiz-Ruiz C; García-Magro N; Negredo P; Avendaño C; Bhattacharya A; Ceusters M; García AG
    Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1
    Ly D; Dongol A; Cuthbertson P; Guy TV; Geraghty NJ; Sophocleous RA; Sin L; Turner BJ; Watson D; Yerbury JJ; Sluyter R
    Purinergic Signal; 2020 Mar; 16(1):109-122. PubMed ID: 32170537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1
    Bartlett R; Sluyter V; Watson D; Sluyter R; Yerbury JJ
    PeerJ; 2017; 5():e3064. PubMed ID: 28265522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
    Apolloni S; Amadio S; Montilli C; Volonté C; D'Ambrosi N
    Hum Mol Genet; 2013 Oct; 22(20):4102-16. PubMed ID: 23736299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis.
    Apolloni S; Amadio S; Parisi C; Matteucci A; Potenza RL; Armida M; Popoli P; D'Ambrosi N; Volonté C
    Dis Model Mech; 2014 Sep; 7(9):1101-9. PubMed ID: 25038061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model.
    Apolloni S; Fabbrizio P; Amadio S; Napoli G; Freschi M; Sironi F; Pevarello P; Tarroni P; Liberati C; Bendotti C; Volonté C
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis.
    Apolloni S; Parisi C; Pesaresi MG; Rossi S; Carrì MT; Cozzolino M; Volonté C; D'Ambrosi N
    J Immunol; 2013 May; 190(10):5187-95. PubMed ID: 23589615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model.
    Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy.
    Jimenez-Pacheco A; Diaz-Hernandez M; Arribas-Blázquez M; Sanz-Rodriguez A; Olivos-Oré LA; Artalejo AR; Alves M; Letavic M; Miras-Portugal MT; Conroy RM; Delanty N; Farrell MA; O'Brien DF; Bhattacharya A; Engel T; Henshall DC
    J Neurosci; 2016 Jun; 36(22):5920-32. PubMed ID: 27251615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P2X7 receptor activation mediates superoxide dismutase 1 (SOD1) release from murine NSC-34 motor neurons.
    Bartlett R; Ly D; Cashman NR; Sluyter R; Yerbury JJ
    Purinergic Signal; 2022 Dec; 18(4):451-467. PubMed ID: 35478453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression.
    Apolloni S; Fabbrizio P; Amadio S; Volonté C
    J Neuroinflammation; 2016 Aug; 13(1):191. PubMed ID: 27549088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
    Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
    Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
    Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of hirsutella sinensis on the disease onset and progression of amyotrophic lateral sclerosis in SOD1
    Shang HY; Zhang JJ; Fu ZF; Liu YF; Li S; Chen S; Le WD
    CNS Neurosci Ther; 2020 Jan; 26(1):90-100. PubMed ID: 31318169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1
    Chiarotto GB; Cartarozzi LP; Perez M; Biscola NP; Spejo AB; Gubert F; França Junior M; Mendez-Otero R; de Oliveira ALR
    J Neuroinflammation; 2019 Nov; 16(1):218. PubMed ID: 31727149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotinamide Riboside and Pterostilbene Cooperatively Delay Motor Neuron Failure in ALS SOD1
    Obrador E; Salvador R; Marchio P; López-Blanch R; Jihad-Jebbar A; Rivera P; Vallés SL; Banacloche S; Alcácer J; Colomer N; Coronado JA; Alandes S; Drehmer E; Benlloch M; Estrela JM
    Mol Neurobiol; 2021 Apr; 58(4):1345-1371. PubMed ID: 33174130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of methylene blue on microglia-induced inflammation and motor neuron degeneration in the SOD1(G93A) model for ALS.
    Dibaj P; Zschüntzsch J; Steffens H; Scheffel J; Göricke B; Weishaupt JH; Le Meur K; Kirchhoff F; Hanisch UK; Schomburg ED; Neusch C
    PLoS One; 2012; 7(8):e43963. PubMed ID: 22952827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models.
    Ono Y; Tanaka H; Takata M; Nagahara Y; Noda Y; Tsuruma K; Shimazawa M; Hozumi I; Hara H
    Neurosci Lett; 2014 Jan; 559():174-8. PubMed ID: 24334165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
    Milanese M; Giribaldi F; Melone M; Bonifacino T; Musante I; Carminati E; Rossi PI; Vergani L; Voci A; Conti F; Puliti A; Bonanno G
    Neurobiol Dis; 2014 Apr; 64():48-59. PubMed ID: 24361555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.